In waning Covid market, MiNK unveils data on natural killer T cell therapy for ARDS, pending contract with DARPA
In an SITC poster, Agenus’ spinout MiNK Therapeutics dropped the results of a Phase I/II study of its lead candidate, made from rare immune cells known as invariant natural killer T cells, or iNKT cells for short, for treating acute respiratory distress syndrome (ARDS), a serious complication of Covid.
MiNK was and still is developing the iNKT therapy, dubbed agenT-797, for treating cancer, but like others, it pivoted during the pandemic and started a small 20-person study in ARDS patients who were intubated or at high risk of being intubated. In the trial, patients who got MiNK’s therapy had a 70% chance of survival compared to 10% in a case control group of 20 patients at 30 days. In a more severe subgroup, three of four patients who were on ECMO, essentially an artificial lung machine, and got agenT-797 on top of that survived through 90 days.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.